Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics is a clinical-stage pharmaceutical company with potential treatments for cancer and rare diseases, and their main programs targeting recurrent glioblastoma and leptomeningeal metastases. They have shown solid progress on clinical trials, with their lead drug RNL being evaluated in a Phase 2 clinical trial and their diagnostic tool CNSide already launched. With major grant wins and economic value propositions supporting the commercial rollout of CNSide, the company has significant potential for growth and success in the market.

Bears say

Plus Therapeutics is facing challenges in securing major contracts for its CNSide product, with only three agreements announced so far. Despite maintaining their revenue estimates for 2026, the company is expecting a decrease in EPS due to adjusting estimates for Q4. Furthermore, the company's recent Q4 2025 results were lower than both their own and consensus estimates, raising concerns about their financial performance.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.